178 related articles for article (PubMed ID: 35313916)
1. Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea.
Choi N; Son KB; Byun J; Yang DW
Global Health; 2022 Mar; 18(1):34. PubMed ID: 35313916
[TBL] [Abstract][Full Text] [Related]
2. Patent challenges and factors associated with successful patent challengers under the patent linkage system: recent evidence from South Korea after the Korea United States free trade agreement.
Son KB; Choi N; Lee B; Byun J; Yang DW; Lee TJ
Global Health; 2021 Sep; 17(1):116. PubMed ID: 34583734
[TBL] [Abstract][Full Text] [Related]
3. Past, present and future of pharmaceutical patents under Korea-US Trade Agreement.
Shin YS
Pharm Pat Anal; 2016 Jul; 5(4):237-48. PubMed ID: 27338849
[TBL] [Abstract][Full Text] [Related]
4. Patenting and patent challenges in South Korea after introducing a patent linkage system.
Son KB
Global Health; 2022 Nov; 18(1):95. PubMed ID: 36371241
[TBL] [Abstract][Full Text] [Related]
5. Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-U.S. Free Trade Agreement in Korea.
Son KB; Bae S; Lee TJ
Int J Health Serv; 2019 Apr; 49(2):306-321. PubMed ID: 30626258
[TBL] [Abstract][Full Text] [Related]
6. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
Son KB; Lopert R; Gleeson D; Lee TJ
Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of the drug patent linkage system in China.
Yao XF
Global Health; 2024 Apr; 20(1):31. PubMed ID: 38622631
[TBL] [Abstract][Full Text] [Related]
8. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
9. Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
Son KB
Front Public Health; 2023; 11():1120729. PubMed ID: 37601172
[TBL] [Abstract][Full Text] [Related]
10. Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics.
Son KB
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):541-548. PubMed ID: 31483158
[No Abstract] [Full Text] [Related]
11. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
12. Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures.
Son KB
Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):815-822. PubMed ID: 33765402
[TBL] [Abstract][Full Text] [Related]
13. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
14. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
15. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
16. Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists.
Alhiary R; Kesselheim AS; Gabriele S; Beall RF; Tu SS; Feldman WB
JAMA; 2023 Aug; 330(7):650-657. PubMed ID: 37505513
[TBL] [Abstract][Full Text] [Related]
17. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.
Darrow JJ; Beall RF; Kesselheim AS
Appl Health Econ Health Policy; 2019 Feb; 17(1):47-54. PubMed ID: 30141133
[TBL] [Abstract][Full Text] [Related]
18. Patent Challenges And Litigation On Inhalers For Asthma And COPD.
Reddy S; Beall RF; Tu SS; Kesselheim AS; Feldman WB
Health Aff (Millwood); 2023 Mar; 42(3):398-406. PubMed ID: 36877911
[TBL] [Abstract][Full Text] [Related]
19. Generic entry, reformulations and promotion of SSRIs in the US.
Huskamp HA; Donohue JM; Koss C; Berndt ER; Frank RG
Pharmacoeconomics; 2008; 26(7):603-16. PubMed ID: 18563951
[TBL] [Abstract][Full Text] [Related]
20. Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study.
Son KB
Front Public Health; 2021; 9():654952. PubMed ID: 33889560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
